Bone:研究揭示了Wnt10a在骨骼、脂肪和肌肉中相互作用的潜在机制

2018-10-17 MedSci MedSci原创

Wnt10a是WNT家族的成员,虽然这种基因的缺乏引起了与牙齿、头发、指甲和皮肤有关的症状,但我们最近证实了涉及骨骼和脂肪的Wnt10a敲除(KO)小鼠的新表型。Wnt10a基因对骨和脂肪的体内作用尚不清楚,Wnt10a信号传导中骨/脂肪和肌肉之间的关系也很有趣。本研究旨在评估Wnt10a KO小鼠与野生型小鼠相比的组织变化,并将结果显示为揭示Wnt10a在骨骼,脂肪和肌肉中的体内相互作用的潜在机

Wnt10a是WNT家族的成员,虽然这种基因的缺乏引起了与牙齿、头发、指甲和皮肤有关的症状,但我们最近证实了涉及骨骼和脂肪的Wnt10a敲除(KO)小鼠的新表型。Wnt10a基因对骨和脂肪的体内作用尚不清楚,Wnt10a信号传导中骨/脂肪和肌肉之间的关系也很有趣。本研究旨在评估Wnt10a KO小鼠与野生型小鼠相比的组织变化,并将结果显示为揭示Wnt10a在骨骼,脂肪和肌肉中的体内相互作用的潜在机制的起点。

观察到Wnt10a小鼠下肢的骨小梁丢失和骨矿化减少。骨髓中的脂肪组织也减少,脂肪细胞分化减少。Wnt10a KO小鼠体脂肪量减少,皮下脂肪中的白色脂肪细胞转变为米色脂肪细胞。尽管骨小梁丧失,但下肢的肌肉重量没有减少,但是Wnt10a KO小鼠的皮下脂肪和腓肠肌中的Gdf8/肌肉生长抑制素表达降低。因此,Wnt10a的体内缺失抑制了成骨活性,促进了白色脂肪细胞的米色脂肪形成并维持了肌肉质量。

这些结果表明Wnt10a对Gdf8的调节可能有助于维持Wnt10a KO小鼠的肌肉质量。这项研究首次在组织学上评估了Wnt10a KO小鼠的骨骼、脂肪和肌肉表型。通过将三种组织一起研究获得的该研究的结果可以影响对涉及Wnt10a基因的体内相互作用的理解。

原始出处:

Tsukamoto M, Wang KY, et al., Findings as a starting point to unravel the underlying mechanisms of in vivo interactions involving Wnt10a in bone, fat and muscle. Bone. 2018 Oct 11;120:75-84. doi: 10.1016/j.bone.2018.10.009.

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (5)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1915190, encodeId=376b191519076, content=<a href='/topic/show?id=05343619cf' target=_blank style='color:#2F92EE;'>#Bone#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3619, encryptionId=05343619cf, topicName=Bone)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7dc7399, createdName=apoenzyme, createdTime=Sat Feb 23 16:13:00 CST 2019, time=2019-02-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1909265, encodeId=da851909265da, content=<a href='/topic/show?id=8039e2512e8' target=_blank style='color:#2F92EE;'>#相互作用#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=21, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=72512, encryptionId=8039e2512e8, topicName=相互作用)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f73a255, createdName=medscijoin, createdTime=Mon Sep 30 11:13:00 CST 2019, time=2019-09-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1471612, encodeId=659114e1612c2, content=<a href='/topic/show?id=c0132410554' target=_blank style='color:#2F92EE;'>#互作#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=24105, encryptionId=c0132410554, topicName=互作)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4dc87121468, createdName=ylz8405, createdTime=Fri Oct 19 14:13:00 CST 2018, time=2018-10-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1598620, encodeId=4dd2159862060, content=<a href='/topic/show?id=c4da18e2588' target=_blank style='color:#2F92EE;'>#WNT#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=21, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=18725, encryptionId=c4da18e2588, topicName=WNT)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=eb3518632538, createdName=zhwj, createdTime=Fri Oct 19 14:13:00 CST 2018, time=2018-10-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=349688, encodeId=968f3496880a, content=xuexile, beContent=null, objectType=article, channel=null, level=null, likeNumber=63, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c33e2412978, createdName=1237db7em74暂无昵称, createdTime=Thu Oct 18 00:21:57 CST 2018, time=2018-10-18, status=1, ipAttribution=)]
    2019-02-23 apoenzyme
  2. [GetPortalCommentsPageByObjectIdResponse(id=1915190, encodeId=376b191519076, content=<a href='/topic/show?id=05343619cf' target=_blank style='color:#2F92EE;'>#Bone#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3619, encryptionId=05343619cf, topicName=Bone)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7dc7399, createdName=apoenzyme, createdTime=Sat Feb 23 16:13:00 CST 2019, time=2019-02-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1909265, encodeId=da851909265da, content=<a href='/topic/show?id=8039e2512e8' target=_blank style='color:#2F92EE;'>#相互作用#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=21, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=72512, encryptionId=8039e2512e8, topicName=相互作用)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f73a255, createdName=medscijoin, createdTime=Mon Sep 30 11:13:00 CST 2019, time=2019-09-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1471612, encodeId=659114e1612c2, content=<a href='/topic/show?id=c0132410554' target=_blank style='color:#2F92EE;'>#互作#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=24105, encryptionId=c0132410554, topicName=互作)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4dc87121468, createdName=ylz8405, createdTime=Fri Oct 19 14:13:00 CST 2018, time=2018-10-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1598620, encodeId=4dd2159862060, content=<a href='/topic/show?id=c4da18e2588' target=_blank style='color:#2F92EE;'>#WNT#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=21, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=18725, encryptionId=c4da18e2588, topicName=WNT)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=eb3518632538, createdName=zhwj, createdTime=Fri Oct 19 14:13:00 CST 2018, time=2018-10-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=349688, encodeId=968f3496880a, content=xuexile, beContent=null, objectType=article, channel=null, level=null, likeNumber=63, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c33e2412978, createdName=1237db7em74暂无昵称, createdTime=Thu Oct 18 00:21:57 CST 2018, time=2018-10-18, status=1, ipAttribution=)]
  3. [GetPortalCommentsPageByObjectIdResponse(id=1915190, encodeId=376b191519076, content=<a href='/topic/show?id=05343619cf' target=_blank style='color:#2F92EE;'>#Bone#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3619, encryptionId=05343619cf, topicName=Bone)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7dc7399, createdName=apoenzyme, createdTime=Sat Feb 23 16:13:00 CST 2019, time=2019-02-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1909265, encodeId=da851909265da, content=<a href='/topic/show?id=8039e2512e8' target=_blank style='color:#2F92EE;'>#相互作用#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=21, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=72512, encryptionId=8039e2512e8, topicName=相互作用)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f73a255, createdName=medscijoin, createdTime=Mon Sep 30 11:13:00 CST 2019, time=2019-09-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1471612, encodeId=659114e1612c2, content=<a href='/topic/show?id=c0132410554' target=_blank style='color:#2F92EE;'>#互作#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=24105, encryptionId=c0132410554, topicName=互作)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4dc87121468, createdName=ylz8405, createdTime=Fri Oct 19 14:13:00 CST 2018, time=2018-10-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1598620, encodeId=4dd2159862060, content=<a href='/topic/show?id=c4da18e2588' target=_blank style='color:#2F92EE;'>#WNT#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=21, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=18725, encryptionId=c4da18e2588, topicName=WNT)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=eb3518632538, createdName=zhwj, createdTime=Fri Oct 19 14:13:00 CST 2018, time=2018-10-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=349688, encodeId=968f3496880a, content=xuexile, beContent=null, objectType=article, channel=null, level=null, likeNumber=63, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c33e2412978, createdName=1237db7em74暂无昵称, createdTime=Thu Oct 18 00:21:57 CST 2018, time=2018-10-18, status=1, ipAttribution=)]
    2018-10-19 ylz8405
  4. [GetPortalCommentsPageByObjectIdResponse(id=1915190, encodeId=376b191519076, content=<a href='/topic/show?id=05343619cf' target=_blank style='color:#2F92EE;'>#Bone#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3619, encryptionId=05343619cf, topicName=Bone)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7dc7399, createdName=apoenzyme, createdTime=Sat Feb 23 16:13:00 CST 2019, time=2019-02-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1909265, encodeId=da851909265da, content=<a href='/topic/show?id=8039e2512e8' target=_blank style='color:#2F92EE;'>#相互作用#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=21, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=72512, encryptionId=8039e2512e8, topicName=相互作用)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f73a255, createdName=medscijoin, createdTime=Mon Sep 30 11:13:00 CST 2019, time=2019-09-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1471612, encodeId=659114e1612c2, content=<a href='/topic/show?id=c0132410554' target=_blank style='color:#2F92EE;'>#互作#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=24105, encryptionId=c0132410554, topicName=互作)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4dc87121468, createdName=ylz8405, createdTime=Fri Oct 19 14:13:00 CST 2018, time=2018-10-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1598620, encodeId=4dd2159862060, content=<a href='/topic/show?id=c4da18e2588' target=_blank style='color:#2F92EE;'>#WNT#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=21, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=18725, encryptionId=c4da18e2588, topicName=WNT)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=eb3518632538, createdName=zhwj, createdTime=Fri Oct 19 14:13:00 CST 2018, time=2018-10-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=349688, encodeId=968f3496880a, content=xuexile, beContent=null, objectType=article, channel=null, level=null, likeNumber=63, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c33e2412978, createdName=1237db7em74暂无昵称, createdTime=Thu Oct 18 00:21:57 CST 2018, time=2018-10-18, status=1, ipAttribution=)]
    2018-10-19 zhwj
  5. [GetPortalCommentsPageByObjectIdResponse(id=1915190, encodeId=376b191519076, content=<a href='/topic/show?id=05343619cf' target=_blank style='color:#2F92EE;'>#Bone#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3619, encryptionId=05343619cf, topicName=Bone)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7dc7399, createdName=apoenzyme, createdTime=Sat Feb 23 16:13:00 CST 2019, time=2019-02-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1909265, encodeId=da851909265da, content=<a href='/topic/show?id=8039e2512e8' target=_blank style='color:#2F92EE;'>#相互作用#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=21, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=72512, encryptionId=8039e2512e8, topicName=相互作用)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f73a255, createdName=medscijoin, createdTime=Mon Sep 30 11:13:00 CST 2019, time=2019-09-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1471612, encodeId=659114e1612c2, content=<a href='/topic/show?id=c0132410554' target=_blank style='color:#2F92EE;'>#互作#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=24105, encryptionId=c0132410554, topicName=互作)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4dc87121468, createdName=ylz8405, createdTime=Fri Oct 19 14:13:00 CST 2018, time=2018-10-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1598620, encodeId=4dd2159862060, content=<a href='/topic/show?id=c4da18e2588' target=_blank style='color:#2F92EE;'>#WNT#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=21, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=18725, encryptionId=c4da18e2588, topicName=WNT)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=eb3518632538, createdName=zhwj, createdTime=Fri Oct 19 14:13:00 CST 2018, time=2018-10-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=349688, encodeId=968f3496880a, content=xuexile, beContent=null, objectType=article, channel=null, level=null, likeNumber=63, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c33e2412978, createdName=1237db7em74暂无昵称, createdTime=Thu Oct 18 00:21:57 CST 2018, time=2018-10-18, status=1, ipAttribution=)]
    2018-10-18 1237db7em74暂无昵称

    xuexile

    0